Status:
COMPLETED
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Lead Sponsor:
GlaxoSmithKline
Conditions:
Measles
Rubella
Eligibility:
All Genders
11-13 years
Phase:
PHASE3
Brief Summary
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year...
Detailed Description
This study included an active control group who received the licensed Priorix (measles, mumps, rubella \[MMR\] vaccine).
Eligibility Criteria
Inclusion
- A male or female subject between 11-13 months of age (i.e. from 11 month birthday until the day before the 14 month birthday) at the time of the first vaccination.
Exclusion
- History of previous measles, mumps, rubella and/or varicella vaccination or disease, or known exposure to any of these diseases within 30 days prior to the start of the trial
- Planned administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 42-56 days after each vaccination
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00127010
Start Date
November 1 2005
End Date
June 1 2006
Last Update
September 26 2016
Active Locations (48)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Brussels, Belgium, 1090
2
GSK Investigational Site
Leuven, Belgium, 3000
3
GSK Investigational Site
Bad Saulgau, Baden-Wurttemberg, Germany, 88348
4
GSK Investigational Site
Bönnigheim, Baden-Wurttemberg, Germany, 74357